IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jonathan W Riess, MD, MSc
Division of Hematology/Oncology, UC Davis Comprehensive Cancer Center
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain
- Hospital Clínico Universitario de Valencia
Valencia, Valencia, Spain
- Hospital Clínico Lozano Blesa
Zaragoza, Zaragoza, Spain
- Hospital Vall D'Hebron
Barcelona, Spain
- Institut Català D'Oncologia (ico) Badalona (catalan Institute of Oncology)
Barcelona, Spain
- Hospital Universitari de Girona Doctor Josep Trueta
Girona, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- Hospital Universitario Virgen de la Victoria
Málaga, Spain
- Velindre Cancer Center
Cardiff, United Kingdom
- Guys and St Thomas Hospital
London, United Kingdom
- City of Hope
Duarte, California, United States
- Uc Davis Cancer Center
Sacramento, California, United States
- University of California San Diego
San Diego, California, United States
- Mid Florida Hematology and Oncology Center
Orange City, Florida, United States
- Montefiore Medical Center
The Bronx, New York, United States
- University of Toledo Medical Center
Toledo, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Virginia Cancer Specialists
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Apr 2022
- Primary completion
- 30 Nov 2025
- Completion
- 8 Feb 2026
- Last update posted
- 8 Apr 2026
- Registered enrollment
- 63
- Registry id
- NCT05077709
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.